Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
You may also be interested in...
To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.
Wells Fargo analyst David Maris warned biopharma investors that the US drug market is on a long-term trajectory toward price controls, which he characterized as an under-appreciated risk for the sector, ahead of President Trump's speech on drug pricing.
Proposed trigger changes will discourage low-quality applications, not disincentivize patent challenges, deputy commissioner suggests at generic association's annual meeting.